Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Discontinuation Outcome in Multiple Myeloma after BCMA-CD3 Bispecific Antibody Treatment
2025-524022-18-00Phase 2Authorised
- Sponsor
- Region Västra Götaland
- Start
- Feb 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elranatamab and teclistamab in multiple myeloma (MM), sponsored by Region Västra Götaland. Primary endpoint: Disease-free survival based on sustained molecular minimal residual disease remission at 6 months and 3 years. Planned start Feb 2026; status: authorised.
02
Drugs
elranatamabteclistamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2025-524022-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524022-18-00.